Bruker Corp (BRKR) Stock Analysis
Verdict: WATCH (do not buy)
Goodwill impairments mask underlying 5.2% organic growth, but high debt and insider selling suggest the post-crash floor isn't yet firm.
Investment score: 48/100
Analysis as of
Is Bruker Corp stock worth reviewing? The TradeMates thesis
The TradeMates model recommends a HOLD. While the 20% haircut reflects a significant goodwill impairment, the underlying 36% revenue growth and 46.7% gross margins remain intact. However, the valuation (68x EV/EBITDA) is still expensive relative to BIO (149x) and RGEN (70x) when adjusted for Bruker's significantly higher leverage.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Bruker Corp opportunities and risks
What speaks for BRKR
- Return to Organic Growth
What speaks against BRKR
- Extreme Debt Leverage
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BRKR | n/a | 2.2x | 68.1x | 46.4% | -2.7% | 1.2% |
| CRL | n/a | 2.8x | n/a | 16.2% | -6.0% | 3.3% |
| AVTR | n/a | 1.4x | 456.0x | 31.8% | -8.8% | 4.9% |
| BIO | 39.9x | 3.5x | 149.2x | 51.9% | 8.6% | 3.9% |
| TEM | n/a | 5.8x | n/a | 64.0% | -17.8% | -3.3% |
| RGEN | 202.4x | 10.8x | 70.1x | 51.1% | 5.3% | 1.3% |
| Peer median | n/a | 3.5x | 70.1x | 51.1% | -6.0% | 3.3% |
Frequently asked questions about Bruker Corp (BRKR)
Is BRKR stock a good investment?
The TradeMates model rates Bruker Corp as WATCH (do not buy) with an investment score of 48/100. The TradeMates model recommends a HOLD. While the 20% haircut reflects a significant goodwill impairment, the underlying 36% revenue growth and 46.7% gross margins remain intact. However, the valuation (68x EV/EBITDA) is still expensive relative to BIO (149x) and RGEN (70x) when adjusted for Bruker's significantly higher leverage. This is algorithmic model output, not personal investment advice.
Is BRKR stock a buy?
The TradeMates model verdict for BRKR is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.